secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-08-12T20:02:53+00:00
Accession:  0001193125-26-346796
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo files June monthly operating report; cash $14.38M, net loss $3.76M in Chapter 11
--------------------------------------------------------------------------------

- Chapter 11 filed June 23, 2026; case No. 26-10989 in Delaware; stock now OTC under SGMOQ.
- Cash balance $14.38M at June 30, 2026; drew $10.5M under initial DIP facility during June.
- June net loss $3.76M; gross income $108,953, G&A $1.10M, reorganization items $2.01M.
- Prepetition unsecured debt $78.13M; total liabilities $89.15M; total assets $153.09M.
- 73 full-time employees as of June 30; professional fees and DIP financing approved by court.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/0001193125-26-346796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526346796/d21956d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer